0000000000448178

AUTHOR

Bernard Chappuis

showing 2 related works from this author

Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2…

2008

To assess the effects of pioglitazone and rosiglitazone on fasting and postprandial low-density lipoprotein (LDL) size and subclasses in patients with Type 2 diabetes.Nine Type 2 diabetic patients (age 61 +/- 10 years, body mass index 30 +/- 5 kg/m(2), glycosylated hemoglobin [HbA1c] 7.5 +/- 0.5%) were randomized in a crossover trial to rosiglitazone 4 mg b.i.d. or pioglitazone 45 mg/day for 12 weeks with an 8-week wash-out period. LDL size and subclasses were determined by non-denaturing polyacrylamide gradient gel electrophoresis. A standardized breakfast was served and variables were assessed after 3 and 6 h.HbA1c, insulin sensitivity (as assessed by the homeostasis model assessment) and…

Malemedicine.medical_specialtyType 2 diabetesRosiglitazonechemistry.chemical_compoundDiabetes mellitusInternal medicinemedicineHumansHypoglycemic AgentsPharmacology (medical)Prospective StudiesTriglyceridesPharmacologyGlycated HemoglobinCross-Over StudiesTriglyceridePioglitazoneCholesterolbusiness.industryGeneral MedicineCholesterol LDLFastingGlucose Tolerance TestMiddle Agedmedicine.diseasePostprandial PeriodLipoproteins LDLPostprandialEndocrinologychemistryDiabetes Mellitus Type 2Low-density lipoproteindense LDL diabetes LDL size pioglitazone postprandial rosiglitazoneElectrophoresis Polyacrylamide GelFemaleThiazolidinedionesbusinessRosiglitazonePioglitazonemedicine.drug
researchProduct

COMPARATIVE EFFECTS OF ROSIGLITAZONE AND PIOGLITAZONE ON FASTING AND POSTPRANDIAL LDL-SIZE AND SUBCLASSES IN PATIENTS WITH TYPE-2 DIABETES

2008

medicine.medical_specialtybusiness.industryGeneral MedicineType 2 diabetesmedicine.diseaseFasting glucosePostprandialEndocrinologyInternal medicineInternal Medicinerosiglitazone pioglitazone fasting glucose postprandial glucose LDL type-2 diabetesMedicineIn patientCardiology and Cardiovascular MedicinebusinessRosiglitazonePioglitazonemedicine.drugAtherosclerosis Supplements
researchProduct